Fauna Unveils ‘Fauna Brain’: An Agentic AI System Accelerating Drug Discovery with Proven Results in Lilly Collaboration

Fauna Bio launched Fauna Brain, an advanced multi-agent AI platform designed to fast-track early-stage drug discovery by autonomously executing research workflows that normally require specialized scientific teams23.

Fauna Brain integrates large-scale comparative genomics data from 292 species, 24 tissues, and 21 time points, leveraging over 46 billion sequence reads and thousands of transcriptomes, proteomes, and epigenomes to identify druggable human targets2.

The platform operates atop Fauna’s Convergence AI suite (including Orca, Centaur, and Pegasus engines), drawing on protective biological mechanisms observed in animals with extreme traits like hibernation or disease resistance to uncover and prioritize novel therapeutic targets23.

Fauna Brain has demonstrated the ability to autonomously identify, rank, and assess drug targets—including synthesizing evidence and generating detailed concept sheets with mechanistic risk-benefit analyses—cutting evaluation time to as little as 2.5 minutes per target at the cost of about $0.013.

Initial impact has been validated:
Two Fauna Brain-prioritized targets have already advanced into funded research collaborations with a major pharmaceutical partner, widely reported as Eli Lilly23.

This platform expansion allows Fauna Bio to pursue a broader and deeper pipeline of drug candidates, dramatically reducing both the time and costs compared to traditional discovery approaches3.

Sources:

2. https://www.businesswire.com/news/home/20250616249385/en/Fauna-Bio-Launches-Fauna-Brain-AI-Platform-to-Accelerate-Drug-Discovery-Inspired-by-Natures-Most-Resilient-Species

3. https://www.synbiobeta.com/read/fauna-bio-unveils-fauna-brain-tm-ai-platform-to-accelerate-drug-discovery-inspired-by-natures-most-resilient-species